John T. Treace Sells $1.37M of Treace Medical Concepts Inc (TMCI) — SEC Form 4, Dec 27, 2021
Open-Market Net Sale · SEC Form 4
−$1,365,270
10b5-1 Plan
Equity position changed by -0.8%
Equity Position
10.8M sh
10,851,214 → 10,769,544
Equity Change
-0.8%
shares held after vs before
Filing Lag
0 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| John T. Treace CIK 0001856380 |
Director
CEO
10% Owner
|
John T. Treace at Treace Medical Concepts Inc
Full insider history
Bought (12 mo)
$1,351,631
Sold (12 mo)
—
More from this insider at Treace Medical Concepts Inc
| 2026-08-24 | Buy | +$246,654 | View |
| 2026-06-11 | Buy | +$210,968 | View |
| 2026-06-01 | Buy | +$177,915 | View |
| 2026-05-28 | Buy | +$340,589 | View |
| 2026-05-14 | Buy | +$375,505 | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common StockF1F2 | 2021-12-22 | S - Sale 10b5-1 | 41,710 D | $16.29 | -$679,356 | 5,485,375 | Direct |
| Common StockF1F3 | 2021-12-23 | S - Sale 10b5-1 | 22,795 D | $16.96 | -$386,542 | 5,462,580 | Direct |
| Common StockF1F4 | 2021-12-27 | S - Sale 10b5-1 | 17,165 D | $17.44 | -$299,373 | 5,445,415 | Direct |
Footnotes (6)
- F1
- Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Show more
- F2
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.59 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Show more
- F3
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.50 to $ $17.29 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Show more
- F4
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.25 to $17.61 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Show more
- F5
- The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee. Show more
- F6
- The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as Trustee or Co-Trustee. Show more
Related filings at Treace Medical Concepts Inc
Institutional Holders
13F holders · Jun 30, 2026
115
institutional managers reporting a position
Largest by reported value
- Armistice Capital, Llc $25.3M
- Bank Of America Corporation $13.2M
- Gagnon Securities Llc $12.1M
5%+ Holders · 13D/G
4 filers
-
John T. Treace 19.2%
Other insiders at Treace Medical Concepts Inc
GET /v1/forms/4/0001567619-21-022542
API docs
View Original SEC Filing